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Human brucellosis has a broad spectrum of clinical mani-
festations, which includes endocarditis, a focal complication 
that is uncommon yet responsible for the majority of asso-
ciated deaths. The most successful treatment outcomes of 
Brucella endocarditis have been reported with usage of both 
antimicrobial agents and surgery. However, there are few 
reports on the treatment of Brucella endocarditis using anti-
biotics only. We report the first case in Korea of Brucella 
endocarditis with aortic valve vegetations and an accom-
panying splenic abscess, which were treated successfully with 
antibiotic therapy alone. 
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INTRODUCTION 
Human brucellosis is a common zoonotic disease, 
which affects various organs and has a broad 
spectrum of clinical manifestations in both humans 
and animals.
1 The infection usually manifests as a 
febrile syndrome with chills, sweating, arthralgia, 
and myalgia without an apparent focus.
1 Endocar-
ditis is a rare complication of Brucellosis: review 
of a large series of 1,500 patients with the disease 
reported only a 0.8% incidence of endocarditis, 
which is the main cause of morbidity and mor-
tality related to this disease.
2
Although the recommended treatment for Brucella 
endocarditis remains controversial, there is con-
sent that antibiotic therapy should be administered 
prior to surgery in patients with left ventricular 
failure caused by severe valvular destruction or a 
malfunctioning prosthetic valve and those with 
abscess formation.
3 However, patients with short 
evolution of the disease and mild cardiovascular 
infection can be treated with antibiotic therapy 
only.
3
The first suspected case of human brucellosis in 
Korea was that of a livestock worker in 2002.
4 
Since then, the incidence of human brucellosis has 
been on the rise. We report the first case of Brucella 
endocarditis with aortic valve vegetation and an 
accompanying splenic abscess, which were treated 
successfully using antibiotic therapy only. 
CASE REPORT 
A 45-year-old male patient, who used to work 
in the livestock industry, was hospitalized with 
symptoms of fever, chills, sweating, headache, 
intermittent myalgia and a past month weight loss 
of 10 kg. He had taken cold medicine, which 
included acetaminophen, mucolytics and antihis-
tamines, for 2 weeks. He had no past medical 
history of rheumatic fever or any other heart 
diseases. His cattle's brucellosis tests from six 
months ago were all negative; in addition, he stated 
that he had never ingested any dairy products 
from his cattle.
His physical examination showed a body tem-
perature of 38.8°C, blood pressure of 102/80 mmHg, 
and a heart rate of 90 beats/minute. A diastolic 
murmur of grade 2 was auscultated at Erb's point. 
Laboratory studies were as follows: hemoglobin 
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Fig. 1. (A) Contrast-enhanced abdomen CT scan reveals 
partial splenic abscess that is a wedge shape (arrow) and
splenomegaly. (B) Twelve months later, follow-up CT scan
reveals normalized spleen size of about 11 cm compared 
with the previous splenomegaly size of 15 cm. A portion 
of the splenic abscess changed into cortical dimpling 
(arrow) with segmental shrinkage.
12.6 g/dL, hematocrit 35.65%, leukocyte 5,580/mm
3 
(granulocyte 51.4%, lymphocyte 40.6%, monocyte 
5.5%), platelet 218,000/mm
3, erythrocyte sedimen-
tation rate (ESR) 29 mm/hour, C-reactive protein 
(CRP) 4.31 mg/mL, aspartate aminotransferase 
(AST) 56 IU/L, alanine aminotransferase (ALT) 52
IU/L, gamma guanosine triphosphate (γ-GTP) 72 
IU/L. All other lab values were normal. Chest X- 
ray did not show any cardiomegaly or enhanced 
opacity of pulmonary vasculature. Electrocardio-
graphy appeared normal without atrial enlarge-
ment, ventricular hypertrophy, ST-T change, or 
dysrhythmia. Abdominal computed tomography 
(CT) scan revealed a 15.6 cm splenomegaly with 
a partial wedge shaped splenic abscess (Fig. 1). 
Transthoracic echocardiography (TTE) showed 
normal left ventricular systolic function. Mild aortic 
and tricuspid valve regurgitation was present. 
TTE also revealed an oscillating vegetation on the 
noncoronary cusp (3 × 5 mm) and right coronary 
cusp (2 × 4 mm) (Fig. 2). The other echocardiogra-
phic parameters were as follows: left ventricular 
end diastolic dimension (LVEDD), 57 mm, left ven-
tricular end systolic dimension (LVESD), 33 mm, 
left ventricular ejection fraction (LVEF), 72%, di-
mension of aortic root, 37 mm, dimension of left 
atrium, 38 mm, pulmonary artery systolic pressure 
(PASP), 31 mmHg, left ventricular septal thickness 
in diastole (LVSTd), 13 mm, and left ventricular 
posterior wall thickness in diastole (LVPWTd), 13 
mm. Serum antibody test using standard tube 
agglutination (STA) upon admission had a positive 
result as the Brucella serologic titer was over by 
1 : 160 dilution (200 IU). Anti-brucella IgG and IgM 
antibodies by ELISA (PanBio #BAB01M, G, 
Australia) were also positive (IgM 48, IgG 31). A 
blood culture test with trypticase soy agar (TSA, 
containing 5% sheep blood) and BACTEC culture 
(PEDS plus media) were used to isolate and iden-
tify the bacteria causing his symptoms. The genus- 
specific bcsp31 (223 bp), omp36 (195 bp), and 16s 
rRNA (905 bp) polymerase chain reaction (PCR) 
identified all the isolates as Brucella species (Fig. 
3).  Brucella abortus bv 1 strain was identified by 
a species-specific associative memory organization 
system (AMOS)-PCR (Fig. 4). 
Gentamycin (160 mg/day, intravenous [IV]), 
rifampicin (600 mg/day, per os [po]) and doxycy-
cline (200 mg/day, po) were administered. Clinical 
symptoms started improving beginning the fourth 
day of treatment and he was discharged on the 
16th day. He was followed up in the outpatient 
department and was given further antibiotic treat-
ment of trimethoprim/sulfamethoxazole (320 mg/ 
1600 mg/day, po), rifampicin (600 mg/day, po) 
and doxycycline (200 mg/day, po). After one month 
of treatment, ESR and CRP were 9 mm/ hour and 
0.09 mg/mL respectively. Two months later, fol-
low-up transesophageal echocardiography (TEE) 
showed no change in the size of the vegetation on 
the noncoronary cusp, while that on the right 
coronary cusp completely disappeared. Seven 
months later, follow up TEE showed complete 
resolution of the remaining vegetation. The patient 
completed the 12 months long drug regimen. 
A
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Fig. 2. (A) Transesophageal echocardiography reveals one vegetation (4 × 2 mm, arrow) on the right aortic coronary cusp
and the other vegetation (5 × 3 mm, arrow head) on the noncoronary aortic cusp upon admission. (B) Two months later, 
follow up transesophageal echocardiography ( T E E )  r e v e a l s  n o  i n t e r v a l  c h a n g e  o f  the vegetation (arrow) size within the
noncoronary cusp, but vegetation within the right coronary cusp was completely resolved. (C) Seven months later, follow
up TEE shows complete resolution of the remained vegetation. 
Fig. 3. Genus-specific PCR. Molecular diagnostic assays 
based on PCR amplification of different genomic targets 
for the identification of Brucella spp. tested of the isolate.
The clinical isolate was tested by the conventional bioche-
mical tests and detected with common genes (BCSP-31 
kDa, OMP2-36kDa, 16S rRNA) of Brucella spp. M, 100 bp 
marker; Lane 1, Brucella abortus ATCC 2308; Lane 2, 
Patient's isolate. 
Fig. 4. Species-specific AMOS-Multi-PCR. We have adopted
Multiplex AMOS-PCR method for the species-specific 
typing of clinical isolate. In the profile of Multiplex 
AMOS-PCR,  B. abortus (biovar 1, 2, 3, 4, 6), B. melitensis
(biovar 1, 2), B. canis, and B. suis (biovar 3) showed char-
acterization patterns into the respective species and four
different amplification patterns were observed. Multiplex 
AMOS-PCR patterns I (200, 600 and 900 bp) were B. 
melitensis (biovar 1, 2), B. abortus (biovar 3, 6), patterns II
(200, 600 and 720 bp) were B. abortus (biovar 1, 2, 4), 
patterns III (600 and 900 bp) were B. canis, B. suis (biovar
3) and patterns IV (200, 720 and 900 bp) were B. abortus
ATCC 7705. The clinical isolate of our patient had identi-
cal patterns as B. abortus biovar 1 (patterns II). Lane 1, 100
bp ladder; Lane 2 & 3, B. melitensis; Lane 4, B. abortus 
ATCC 7705; Lane 5, B. abortus bv.1; Lane 6, B. abortus bv.
3; Lane 7, B. abortus bv.6; Lane 8, B. abortus bv.2; Lane 9, 
B. abortus bv4; Lane 10, S19; Lane 11, RB51; Lane 12, B.
canis; Lane 13, B. suis; Lane 14, B. ovis; Lane 15, other 
patient's isolate (B. abortus bv.1); Lane 16, our patient's 
isolate. 
Therapy side effects of neutropenia, hepatitis, or 
skin eruption were not observed. Twelve months 
later, we followed up with an abdominal CT scan, 
serological assay, and blood culture. Abdominal 
CT scan showed a normalized spleen size of about 
11 cm compared to the previous splenomegaly 
size of 15 cm. The partial splenic abscess changed 
into cortical dimpling with segmental shrinkage 
without any additional abscess formation (Fig. 1). 
Follow-up serum antibody test results were STA 
1:20 (24 IU); ELISA tests were IgM < 11 and IgG 
19 and blood culture tests showed no organisms. 
The patient has been followed up with control 
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DISCUSSION 
Brucellosis is a zoonotic disease that is distri-
buted worldwide, yet still remains endemic in 
some developing countries. Human brucellosis is 
usually caused by Brucella melitensis, B. abortus, B. 
suis, and rarely by B. canis.
5 Between 2002 and 2006 
human brucellosis in Korea showed an incidence 
of 0.01/100,000 (1 patient) and 0.44/100,000 (215 
patients) respectively. B. abortus was the most fre-
quently isolated strain in human cases of brucel-
losis, reaching some 99% of total cases.
6 The 
incidence of Brucella in the province in which the 
patient lived was the same as for the Republic of 
Korea.
6 Brucella spp. are usually transmitted from 
affected animals to humans by ingestion of un-
pasteurized dairy products and on rare occasions 
are transmitted by inhalation or by direct animal 
contact.
7 Transmission, however, cannot occur 
through direct physical contact between humans. 
Brucellosis develops more frequently in young 
male patients, especially slaughterhouse workers, 
farmers, veterinarians, and laboratory workers.
7 
Human brucellosis is diagnosed using clinical 
symptoms and signs, serum antibody test, and 
isolation of Brucella spp. from blood or other 
tissues. Biotypes are determined by electrophoresis. 
Diagnosis of Brucella endocarditis is made by 
detection of vegetations in an echocardiogram and 
isolation of Brucella spp. from blood or tissue 
culture.
8 The usually affected valves are aortic and 
mitral, being aortic the most common.
9-12 Although 
the mortality rate for brucellosis is less than 1%, 
endocarditis accounts for 80% of these deaths.
2 
Endocarditis presents with heart failure, acute aortic 
or mitral valve insufficiency, bradyarrhythmia, 
cardiac fistula, microabscess within cusps, calcifi-
cation, or commissure degeneration.
9,13,14 Valvular 
destruction resulting in left ventricular failure is 
the most common complication. Also septic emboli 
might cause embolic events in several organs.
Brucella spp. are a homogenous group of gram- 
negative coccobacilli, which are ingested by cells 
of the monocyte-macrophage system and can 
survive and replicate within them.
15 This intracel-
lular lifestyle of the organism makes it more dif-
ficult to kill using antibiotic therapy. Also, primary 
treatment of human brucellosis is prone to fail 
because of an oftentimes delayed diagnosis, the 
tendency for the disease to recur, and its chronic 
clinical course. Human brucellosis usually has a 
severe progression, thus early diagnosis is crucial 
for adequate treatment. The treatment regimen 
and duration for Brucella endocarditis are not yet 
established. The therapeutic approach for Brucella 
endocarditis traditionally involved the combina-
tion of medical and surgical treatment,
10,16,17 with 
significant mortality reduction.
14 When there are 
signs of left ventricular failure due to severe val-
vular destruction or dysfunction of the prosthetic 
valve, valvular abscess formation or a life-threa-
tening embolic event, surgery is deemed neces-
sary after attempting to stabilize the patient first 
by medical treatment. In those conditions, medical 
treatment cannot be adequate, if used alone. But 
if the clinical course is short: less than 2 months, 
and shows mild heart involvement without left 
ventricular failure, treatment with antibiotics alone 
may be attempted.
18 There have been occasional 
reports on previous cases of complete remission 
with medical treatment alone.
2,18-20  Reguera et al. 
reported that the triple combination of streptomycin 
for the first three weeks, followed by doxycycline 
and rifampicin without surgery for the next three 
months showed successful treatment in a Brucella 
endocarditis patient.
18 Three out of eleven patients 
with  Brucella endocarditis received only medical 
treatment, with favorable results. Early surgical 
treatment was undertaken in the other eight 
patients. Mert et al. used a triple antibiotics com-
bination regimen of doxycycline, ciprofloxacin, 
and trimethoprim/sulfamethoxazole for four 
months with satisfactory clinical results.
2 In our 
case, there was a splenic abscess resulting from 
septic emboli, but it was not life-threatening. An 
abdominal CT scan revealed the small area of 
very early splenic abscess formation that did not 
have a liquid component, which thereby could not 
be drained. Clinical manifestations such as fever 
and chills improved very quickly; ESR and CRP 
decreased rapidly. Therefore, drainage or splenec-
tomy was not performed. Also the evolution was 
short without left ventricular failure, which made 
medical treatment alone a successful therapy. 
There seems to be unanimous agreement that the 
treatment period of Brucella endocarditis should 
be prolonged compared to Brucellosis without 
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published report of Brucella endocarditis,
2 regimen 
and duration of antibiotic therapy may differ 
among various centers, depending upon clinical 
behaviour of the patients.
We treated the patient with antibiotic therapy 
for twelve months to prevent relapse, with com-
plete resolution of the valvular vegetation without 
ever using surgery. We decided to prolong the 
duration of the drug regimen since medical treat-
ment was our main and only mode of therapy. 
We used gentamicin, rifampicin, and doxycycline 
for the first month, followed by a triple combina-
tion of antibiotics including trimethoprim/sulfa-
methoxazole, rifampicin, and doxycycline for 11 
months as outpatient medications. The treatment 
response was quite good showing no side effects, 
disappearance of the valvular vegetation and 
splenic abscess, and no illness relapses.
Nevertheless, until now, antibiotic treatment 
alone in Brucella endocarditis has been reported in 
isolated cases (in 14 adult patients) in literature
2 
and neither the combination of drugs nor duration 
of treatment is well established. As we have seen 
in our case, with select patients and disease 
presentations, the option of medical therapy alone 
may be considered as an equally effective alterna-
tive to the medical-surgical strategy. Further pro-
spective studies are required to establish a treat-
ment guideline to the various forms of Brucella 
endocarditis. 
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